Results 201 to 210 of about 112,813 (257)
Some of the next articles are maybe not open access.
Haemophilia, 1995
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire +4 more sources
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire +4 more sources
Antihemophilic Factor (Factor VIII)
Annals of Internal Medicine, 1978Antihemophilic factor (Factor VIII) is an agent in normal plasma that corrects the coagulative defect of classic hemophillia. The plasma of hemophiliacs contains normal amounts of a variant of antihemophilic factor deficient in clot-promoting properties. In contrast, von Willebrand's disease is usually associated with a true deficiency of this protein.
openaire +2 more sources
2001
The differential diagnosis in the bleeding patient includes inhibitory antibodies to blood coagulation proteins. Factor VIII (fVIII) is the most commonly targeted coagulation protein by the immune system. FVIII inhibitors arise as alloantibodies in transfused hemophiliacs and as autoantibodies in nonhemophiliac populations (1, 2, 3, 4). They develop in
P, Lollar +3 more
openaire +2 more sources
The differential diagnosis in the bleeding patient includes inhibitory antibodies to blood coagulation proteins. Factor VIII (fVIII) is the most commonly targeted coagulation protein by the immune system. FVIII inhibitors arise as alloantibodies in transfused hemophiliacs and as autoantibodies in nonhemophiliac populations (1, 2, 3, 4). They develop in
P, Lollar +3 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1985
To the Editor.— Dr Waddell and colleagues 1 described the use of porcine factor VIII concentrate in a patient with factor VIII inhibitor. They gave in detail the disadvantages and complications of this material and prothrombin complex concentrates.
openaire +2 more sources
To the Editor.— Dr Waddell and colleagues 1 described the use of porcine factor VIII concentrate in a patient with factor VIII inhibitor. They gave in detail the disadvantages and complications of this material and prothrombin complex concentrates.
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1986
To the Editor.— Rock et al 1 reported that in studies in 1982, the stated content of ampules of lyophilized antihemophilic factor (AHF, factor VIII) concentrates often exceeded the measured content, as assayed in the authors' laboratory. They stated that this discrepancy, with its implications of systematic undertreatment of classic hemophilia, has ...
openaire +2 more sources
To the Editor.— Rock et al 1 reported that in studies in 1982, the stated content of ampules of lyophilized antihemophilic factor (AHF, factor VIII) concentrates often exceeded the measured content, as assayed in the authors' laboratory. They stated that this discrepancy, with its implications of systematic undertreatment of classic hemophilia, has ...
openaire +2 more sources
Factor VIII (Anti-hemophilic factor)
Journal of Chronic Diseases, 1970Abstract Factor VIII is a compound of high molecular weight which interacts with activated factor IX, calcium, and phospholipid to generate thromboplastin (activated factor X) for blood coagulation. It has the electrophoretic mobility of an α-2 globulin, and probably consists of both glycoprotein and phospholipid.
openaire +2 more sources
Porcine Factor VIII in Factor VIII Antibody-Positive Hemophiliacs
Journal of Interferon Research, 1994rected against the factor VIII protein, and completely or partially neutralizing the plasma coagulant activity of the clotting factor, is associated with a variety of diseases, and these antibodies are often the cause of the life-threatening bleeds. Such inhibitors, designated as acquired hemophilia, are uncommon (found in 0.2-1.0 previously normal ...
openaire +2 more sources